Photoaged Cell Antigen Composition Using Surface Marker Genes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack specific markers for photoaged cells, making it difficult to target drug therapy effectively and induce immunity against photoaging.
Innovation Solution
Identification of 10 genes (GPR17, CD34, GABRR1, OR2AG2, CMKLR1, CDH19, CD93, AVPR2, CCR7, and OXGR1) as photoaged cell surface markers, and development of antigen and antibody compositions to target and induce immunity against photoaged cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If SA-β-Gal and p16 are used as cell aging markers, then cell aging detection is possible, but they are not specific to photoaged cells and cannot be used for targeted drug therapy
Solution Approach 1:
The invention segments the cell aging detection field into two distinct categories: natural aging markers (SA-β-Gal, p16) and photoaging-specific markers (GPR17, CD34, GABRR1, OR2AG2, CMKLR1, CDH19, CD93, AVPR2, CCR7, OXGR1). This segmentation allows each marker set to serve its specific purpose without cross-contamination of functionality.
Solution Approach 2:
The invention extracts photoaging-specific surface markers from photoaged cells through comparative gene expression analysis, separating them from general aging markers. This extraction enables the development of targeted therapies specifically for photoaged cells without affecting naturally aged cells.
2Adaptability or versatility
If general aging markers are used for therapy, then broad aging coverage is achieved, but specificity to photoaged cells is lost
Solution Approach 1:
The invention applies local quality by assigning different marker profiles to different aging types: photoaged cells express specific surface markers (GPR17, CD34, etc.) while naturally aged cells express different markers (SA-β-Gal, p16). This local differentiation enables precise targeting of photoaged cells with photoaging-specific therapies.
Solution Approach 2:
The invention creates a copy of the photoaged cell surface marker profile through identification and characterization of specific genes (GPR17, CD34, GABRR1, OR2AG2, CMKLR1, CDH19, CD93, AVPR2, CCR7, OXGR1). This copied marker profile serves as a template for developing specific diagnostic and therapeutic interventions.
3Ease of manufacture
If no specific photoaged cell markers are available, then research simplicity is maintained, but drug therapy targeting and immune response induction become impossible
Solution Approach 1:
The invention performs preliminary action by proactively identifying and characterizing photoaged cell surface markers (GPR17, CD34, GABRR1, OR2AG2, CMKLR1, CDH19, CD93, AVPR2, CCR7, OXGR1) before therapeutic development. This preliminary marker identification enables subsequent targeted drug therapy and immune response induction without requiring additional complex research steps.
Data Source
AI summary
This invention provides method for inducing immunity targeting photo aged cells, or antibodies or binding fragments thereof targeting photo aged cells. Specifically, the invention provides antigen composition which contain at least one polypeptide selected from the group consisting of immunogenic GPR17 polypeptides, immunogenic CD34 polypeptides, immunogenic GABRR1 polypeptides, immunogenic OR2AG2 polypeptides, immunogenic CMKLR1 polypeptides, immunogenic CDH19 polypeptides, immunogenic CD93 polypeptides, immunogenic AVPR2 polypeptide, immunogenic CCR7 polypeptide, and immunogenic OXGR1 polypeptide.Such at least one polypeptide is bound to a carrier protein or not bound to a carrier protein. The antigen composition is for inducing immunity against photo aged cells in a subject.